Literature DB >> 6206539

Angiogenesis: initiation and modulation.

J Folkman.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6206539

Source DB:  PubMed          Journal:  Symp Fundam Cancer Res        ISSN： 0190-1214


× No keyword cloud information.
  6 in total

Review 1.  Molecular targets and targeted therapies in bladder cancer management.

Authors:  Ramy F Youssef; Anirban P Mitra; Georg Bartsch; Peter A Jones; Donald G Skinner; Richard J Cote
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226

2.  Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models.

Authors:  Patricia Alamo; Alberto Gallardo; Miguel A Pavón; Isolda Casanova; Manuel Trias; Maria A Mangues; Esther Vázquez; Antonio Villaverde; Ramon Mangues; Maria V Céspedes
Journal:  Dis Model Mech       Date:  2014-01-30       Impact factor: 5.758

3.  The proangiogenic effect of iroquois homeobox transcription factor Irx3 in human microvascular endothelial cells.

Authors:  Kisha Scarlett; Vaishnavi Pattabiraman; Petrina Barnett; Dong Liu; Leonard M Anderson
Journal:  J Biol Chem       Date:  2014-12-15       Impact factor: 5.157

4.  Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy.

Authors:  Wei Cao; Enguang Ma; Li Zhou; Tan Yuan; Chunying Zhang
Journal:  World J Surg Oncol       Date:  2017-03-20       Impact factor: 2.754

5.  A unique family of endothelial cell polypeptide mitogens: the antigenic and receptor cross-reactivity of bovine endothelial cell growth factor, brain-derived acidic fibroblast growth factor, and eye-derived growth factor-II.

Authors:  A B Schreiber; J Kenney; J Kowalski; K A Thomas; G Gimenez-Gallego; M Rios-Candelore; J Di Salvo; D Barritault; J Courty; Y Courtois; M Moenner; C Loret; W H Burgess; T Mehlman; R Friesel; W Johnson; T Maciag
Journal:  J Cell Biol       Date:  1985-10       Impact factor: 10.539

6.  Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.

Authors:  P H Jones; K Christodoulos; N Dobbs; P Thavasu; F Balkwill; A D Blann; G J Caine; S Kumar; A J Kakkar; N Gompertz; D C Talbot; T S Ganesan; A L Harris
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.